Craig-Hallum analyst Alex Fuhrman raised the firm’s price target on LifeMD to $15 from $10 and keeps a Buy rating on the shares. The firm notes LifeMD reported better-than-expected Q4 results and raised its 2024 revenue outlook, supporting its view that medically supported weight loss is the future of weight management.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LFMD:
- LifeMD Reports Fourth Quarter 2023 Results
- Lifemd, Inc. (LFMD) Q4 Earnings Cheat Sheet
- Medifast price target lowered to $40 from $67 at DA Davidson
- LifeMD to Participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference
